icon-folder.gif   Conference Reports for NATAP  
  EASL - The International Liver Congress 2014
49th Annual Meeting of the European
Association for the Study of the Liver
London, United Kingdom  April 9-13
Back grey_arrow_rt.gif
Response-Guided Peginterferon Alfa-2a (PegIFN Alfa-2a) Therapy in Patients with HBeAg-Positive Chronic Hepatitis B (CHB)
  Reported by Jules Levin
EASL 2014 April 9-13 London, UK
J. Hou,1 H. Ma,2 J. Sun,1 Q. Xie,3 Y. Xie,4 Y. Sun,5 H. Wang,6 G. Shi,7 M. Wan,8 J. Niu,9 Q. Ning,10 Y. Yu,11 Y. Xie12
1Hepatology Unit, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Province, China; 2Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing, Xuanwu District, China; 3Department of Infectious Diseases, Shanghai Ruijin Hospital, Jiaotong University School of Medicine, Shanghai, China; 4Liver Disease Department, Beijing Ditan Hospital, Beijing, Chongyang District, China; 5Department of Infectious Diseases, Tangdu Hospital, The Fourth Military Medical University, Xi'an, Shaanxi Province, China; 6Liver Disease Department, Peking University People's Hospital, Beijing, China; 7Department of Infectious Diseases, Huashan Hospital affiliated to Fudan University, Shanghai, China; 8Department of Infectious Diseases, Shanghai Changhai Hospital, Shanghai, China; 9Department of Liver Disease, First Hospital of Jilin University, Changchun, Jilin Province, China; 10Department of Infectious Diseases, Wuhan Tongji Hospital affiliated to Huazhong Technology University, Tongji Medical College, Wuhan, Hubei Province, China; 11Department of Infectious Diseases, Peking University First Hospital, Beijing, China; 12Shanghai Roche Pharmaceuticals Co. Ltd, Shanghai, China